Clinical Trial Update: Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a personalized caplacizumab regimen guided by ADAMTS13 activity in adults with acquired thrombotic thrombocytopenic purpura has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• Caplacizumab (caplacizumab)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | Status: TERMINATED